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Chapter 1 
Cloning Rhodopsin: An Introduction 
 
1.1 What are GPCRs? 
 Examining the role and function of G-protein coupled receptors 
(GPCRs) within the human body is critical.  GPCRs are transmembrane 
proteins (Trabanino et al., 2004) and encompass an estimated 950 genes 
within the human genome (Fredriksson and Schioth, 2005; Mirzadegan et al., 
2003; Takeda et al., 2002).  Their importance rests upon their ability to 
transduce extracellular signals, detect and mediate hormonal and sensory 
stimuli (Heideman and Bourne, 1990), and participate in electron transfer and 
ion transport (Trabanino et al., 2004).   
 
1.2 Mechanism of action 
 GPCRs consist of 7 transmembrane helices; hence, inclusion within 
the 7-transmembrane receptor family (Peirce et al., 2002; Leftkowitz, 2004).  
They possess an extracellular N-terminus, 3 extracellular loops, 3 intracellular 
loops, and an intracellular C-terminus (Salom et al., 2005).  The activation of 
a GPCR occurs from the binding of an extracellular ligand (receptor-specific) 
to its transmembrane domain.  Immediately after ligand binding, the GPCR 
undergoes a conformational change that allows for the binding of a G-protein 
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to the intracellular domain of the GPCR, causing the activation of the G-
protein and the internal relaying of the extracellular signal.  However, various 
subclasses of GPCRs are highly similar in structure and are affected not only 
by the agonists and antagonists within their individual subclass, but by the 
agonists and antagonists of other subclasses as well.  This most often results in 
unwanted side effects.  Drug design targeting only one GPCR is frequently 
encountered with difficulty and frequently results in adverse side effects 
(Trabanino et al., 2004).  Yet, of the presently available therapeutic drugs, 
approximately 40% of them target GPCRs (Muller, 2000; Sautel et al., 2000).   
 Properly functioning GPCRs are critical components of normal body 
function and sound health.  Minor mutations in GPCR structures potentially 
result in diseases such as diabetes and hypertension (mutated in the Glucagon 
receptor), dwarfism (deficient Growth hormone releasing hormone), obesity 
(malfunctioning ß-3-Adrenoceptor), and retinitis pigmentosa (mutated 
Rhodopsin) (Wilson, et al., 1998).  Other manifested conditions resulting from 
deficient GPCRs include: allergies, anxiety, asthma, congestive heart failure, 
migraines, Parkinson’s, and ulcers (Wilson and Bergsma, 2000). 
 Fully operative GPCRs are therefore essential in proper conduction of 
many biological processes and malfunctioning GPCRs are potentially 
detrimental.  Pharmaceutical companies are diligent in their attempts to design 
therapeutic agents and improve existing ones to mimic the natural agonists 
and antagonists that are specific in their target of GPCRs.  These companies 
would be more successful in their efforts if the identity and structures of more 
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GPCRs were known.  However, much of what is currently known about 
GPCR structure was based on X-ray crystallographic measurements of 
rhodopsin.  This was the only GPCR with a known structure until the recent 
determination of the crystal structure of the human ß2 adrenergic G-protein 
coupled receptor (Rasmussen et al., 2007).   
 
1.3 Why study rhodopsin? 
 Rhodopsin is the prototype for GPCRs and therefore widely studied 
(Menon et al., 2001; Okada et al., 2001; Shichide and Yamashita, 2003).  The 
extensive study conducted on rhodopsin is based on its ability to be highly 
expressed in eyes, availability and access for electrophysiological 
manipulations, rapid, quantifiable conversion of its chromophore1 ligand 
between inverse states, and its vital role in vision (Ebrey and Koutalos, 2001; 
Hargrave, 2001; Okada et al., 2001; Okada and Palczewski, 2001; Filipek et 
al., 2003(b)).  The crystallized structure of rhodopsin is invaluable to current 
information collected on GPCRs.  Earliest crystallized structures detailed the 
helical arrangements, interhelical interactions, cytoplasmic helix 8, 
chromophore binding site, and extracellular ligand binding interactions in 
other types of GPCRs (Palczewski et al., 2000).  The advent of high resolution 
diffracted rhodopsin crystals provided further in-depth analysis on the 
cytoplasmic loops and water molecule interactions of the chromophore (Li et 
al., 2004; Okada et al., 2004).   
                                                 
1 A chromophore is a pigmented molecule that exhibits color due to its absorption of specific 
wavelengths of light.  The chromophore in rhodopsin consists of the covalent interactions of 
the protein opsin and retinal.      
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1.4 What is rhodopsin? 
 Rhodopsin, an extremely light-sensitive membrane protein, is 
classifiable as photosensitive (Salom et al., 2005).  Rhodopsin is composed of 
a retinal-protein complex, where retinal is covalently bonded to opsin 
(Wolken, 1995).    Formation of the covalent bond occurs when an aldehyde 
group within retinal bonds to a lysine residue (ε-amino acid) in opsin, creating 
a protonated Schiff base.  As rhodopsin absorbs a photon of light, 11-cis 
retinal is photoisomerized to the all-trans form, generating the active form.   
 
                           Figure-1.1  Structures of 11-cis and all-trans retinal. 
 
 Further, rhodopsin and retinal are universally found in all animal 
retinas.  Even unicellular organisms, such as algae, halophilic bacteria, and 
protozoa utilize rhodopsins which function as light detectors for phototactic 
movement rather than visual excitation as in animals (Wolken, 1995). 
 5 
 In its inactive form rhodopsin exhibits red to purple hues and absorbs 
light at 500 nm.  Contrastingly, when it is activated by light, it bleaches to a 
white color and absorbs light at 370 nm (Wolken, 1995).  Photobleaching, 
fortunately, is avoidable by conducting rhodopsin experiments in the dark 
(Salom et al., 2005).   
 In previous procedures, rhodopsin has been extracted from fresh 
bovine retinas (Salom et al., 2005; Tachibanaki, et al., 1998).  By expressing 
bovine rhodopsin in Escherichia coli (E. coli) (or other unicellular organisms) 
through cloning, extraction of the protein is cheaper, less complex, and 
advantageous.     
 
1.5 Importance of cloning 
 The fields of biology, medicine, and biotechnology have been 
revolutionized through the employment of recombinant DNA technology with 
gene cloning as its central component.  As a vital tool in biology, gene cloning 
conveniently isolates a desired gene, further allowing its assessment.  Gene 
cloning has also provided a way for mammalian proteins and genes to be 
inserted and produced in bacterial cells.  Cloned genes are frequently 
manipulated and made to exist and function in an organism in which it is not 
naturally found (Brown, 1990).  Nevertheless, gene cloning has significantly 
impacted biological research and biotechnology, and the information obtained 
from the structure and function of a cloned gene is very valuable (Brown, 
1990).    
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1.6 What is gene cloning?   
 The process of gene cloning can best be conveyed in a series of basic 
steps.  In order for the cloning process to begin, two essential components are 
needed, purified DNA from the cloning vehicle and purified DNA from the 
prospective gene to be cloned.   
1. The prospective gene to be cloned is inserted into a vector, or a 
circular piece of DNA.  The cloned gene plus the vector is a product 
called recombinant DNA.   
2. The vector’s primary function is to transport the gene to be cloned into 
a host cell, which is usually a bacterium.  So in essence, the vector acts 
as a vehicle.  In the experiment, E.coli cells are used.   
3. When in the host cell, the vector multiplies and produces identical 
copies of itself along with the inserted gene.   
4. As the host cell divides, copies of the vector containing the cloned 
gene are passed on to its progeny.   
5. The host cell continuously divides until it forms a colony – a collection 
of cells, identical to the host, that all contain the recombinant DNA 
molecule.   
 The single most important aspect of the gene cloning process is the 
method by which a recombinant DNA molecule is transported and integrated 
into the host cell.  In order for a vector to perform its function as a vehicle of 
cloning, it must possess two key features:  it must be readily and easily able to 
enter the host cell, and it must be self-replicating or able to produce multiple 
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copies of itself.  Fortunately, two types of DNA, plasmids and bacteriophages, 
are natural cloning vehicles that exist to facilitate the cloning process.  
Plasmids are small, circular extrachromosomal pieces of DNA that can 
replicate independently of the host cell’s chromosome.  Bacteriophages, on 
the other hand, are viral chromosomes that invade and infect bacteria.   
(Brown, 1990).   
 
The Cloning Process 
    Figure-1.2  Summarizes the gene cloning process.  Figure is adopted from 





1.7 Problems with cloning 
 Cloning a foreign gene into E.coli, specifically a mammalian protein, 
is not without complications.  Difficulties often ensue with large-scale 
expression of protein from these cloned genes.    Problems found on the 
transcription and translation levels, whether in between or after both stages, 
are at the cellular level.   
1. One common problem arising during the transcription phase is the 
presence of a sequence within the foreign gene that performs as a 
termination sequence within E. coli.   The aforementioned sequence is 
innocuous within the native host cell; nevertheless, it causes an 
untimely loss of gene expression in E.coli.   
2. Between transcription and translation one major problem is the 
presence of introns in the non-native gene.  The removal of introns 
must occur before the non-native gene can be cloned into E.coli 
because the bacteria are incapable of excising the introns.   
3. Problems surfacing at the translation phase are complex and surround 
the use of codons.  Even though the same genetic code is employed by 
almost all living creatures, some organisms exhibit a preference for 
select codons.  Transfer RNAs (tRNAs) preference for the use of 
certain codons in E.coli may cause an over abundance of that specific 
tRNA and relatively little amounts of various types of tRNAs for 
decoding the infrequent codons.  If the cloned gene has a relatively 
large amount of unfavorable codons (in relation to E.coli) then the 
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translation phase in E.coli may be thwarted by low levels of the 
infrequent tRNAs.   
4. Immediately after translation, the cloned gene product may be 
subjected to rapid degradation.  The use of a mutant E.coli strain 
(which lacks many proteases2) smartly avoids the degradation of the 
cloned gene product.  An additional problem that may surface after the 
completion of translation involves processing.  In most organisms, 
sugar groups are added to proteins (specifically those from animals) 
after translation, and addition of these functional groups aids normal 
protein functioning.  E.coli, however, will not add the sugar groups to 
the recombinant proteins, which results in the formation of a non-
functional protein.   
5. At the cellular level, a cloned mammalian gene may be harmful to the 
host cell.  Even when not toxic to the bacterial cells, fast expression of 
the recombinant protein is thought to cause delayed growth and 
cellular instability, especially when compared to an E.coli cell lacking 
the recombinant gene (Brown, 1990).      
 
1.8 Summary   
 Cloning a mammalian gene into bacterial cells is a huge undertaking 
as uncertainties lie in the ability of the cloned gene to be expressed.  Despite 
problems associated with mammalian gene cloning, an optimistic outlook 
                                                 
2 Proteases are enzymes that solely function to degrade proteins into their constituent 
peptides. 
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should still be employed because not all recombinant genes (when expressed 
in E.coli) fail to produce insufficient amounts of recombinant proteins.  This is 
reason enough to believe the cloning of bovine rhodopsin into E.coli will 
work.   
 In the current experiment, the bovine rhodopsin protein, a mammalian 
gene, has been cloned into a non-native E.coli strain UT5600.  The main goal 
is to assess the capability of the bovine rhodopsin gene, a GPCR, to be 




















 Before the cloning process can ensue, two essential components are 
needed, the cloning vehicle and purified DNA from the prospective gene to be 
cloned.  The pBAD TOPO vector was used as a cloning vehicle in the 
experiment, and the prospective gene to be cloned was the Bovine rhodopsin 
gene.   
 
2.1 Cloning Vector 
 The pBAD TOPO TA Expression kit purchased from Invitrogen was 
used to conduct the cloning process.  The PBAD TOPO plasmid contains 
special properties making it a suitable, efficient cloning vehicle.  These two 
properties are: 1). A topoisomerase that is already bound to the pBAD TOPO 
vector and 2).  A solitary 3’-thymidine (T) overhang on both ends of the 
vector.   (Thymidine or deoxythymidine is one of the 4 bases found in DNA 
that pairs with deoxyadenosine (A).)  
 The 3’-(T) overhang’s principal purpose is to bind to the PCR product 
(the prospective gene to be cloned) which contains (A) overhangs, thus 
constituting the self-ligating properties of the pBAD TOPO vector.  
Consequently, the use of a ligase to bind the PCR product to the pBAD TOPO 
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vector is unnecessary.   A Taq polymerase (which will be subsequently 
discussed and also supplied by the pBAD TOPO TA Expression kit) is 
responsible for adding a single (A) to either ends of the PCR product.   
Functions of the Vaccinia Topoisomerase 1 
 Bound to the pBAD TOPO vector is a topoisomerase 13 derived from 
the Vaccinia virus.  The Vaccinia topoisomerase 1 is 314 amino acids in 
length (Shuman and Moss, 1987), and its primary function is to bind to duplex 
DNA and cleave the phosphodiester backbone of one strand (Shuman, 1994).  
The extreme sequence specificity of Vaccinia topoisomerase 1 allows it to 
recognize and cleave DNA at the 5’ CCCTT in the scissile strand (Shuman 
and Prescott, 1990; Shuman and Prescott, 1991a. 1991b).  Also, it is an 
especially useful tool because it operates as a site-specific restriction 
endonuclease, which selectively cleaves DNA at highly specific sites; 
however, it also religates DNA strands with great proficiency.  Restriction 
endonucleases have been traditionally used to cleave DNA at specific sites to 
produce linear DNA that would then be religated at their ends with DNA 
ligase.  With the advent of Vaccinia topoisomerase 1, what was once a two-
step method for inserting a non-native gene into a vector is now one single 
step.  Furthermore, this single-step method is used in vitro to label DNA ends 
and to clone DNA molecules (Shuman, S., 1994).  Moreover, Invitrogen has 
utilized the specificity of and the discriminatory power in end ligation of 
Vaccinia topoisomerase 1 and incorporated it into the pBAD TOPO® vector.   
                                                 
3 A topoisomerase is an enzyme that functions to alter and manipulate DNA structure whether 
by purposefully introducing supercoils or contrastingly, relieving supercoils in the 
conformation of DNA (Brown, 1990).   
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2.2 Properties of PCR 
 An exciting moment in scientific history occurred during 1985-1986, 
when researchers at Cetus Corporation, USA, established a revolutionary in 
vitro technique for amplifying DNA fragments.  This process is called the 
polymerase chain reaction, but is more commonly referred to as PCR 
(Chawla, 2000).  
 PCR is especially useful because it quickly and easily amplifies a 
minute amount of DNA.   Amplification of a DNA sequence in PCR occurs in 
3 main steps. 
1. The double stranded DNA template is heated to 94 degrees Celsius to 
achieve denaturation. 
2. Synthetic DNA primers anneal to the target sequences on either side of 
the DNA region to be amplified.  This process is carried out at 35-65 
degrees Celsius. 
3. DNA synthesis of the targeted region occurs from the 3’ hydroxyl end 
of each DNA primer by Taq polymerase.  This step occurs in repetitive 
cycles, and the primer extension products of antecedent cycles serve as 
a new template for subsequent cycles.  Hence, the number of targeted 
DNA copies may double each cycle, hence, the term amplification.   
It should be noted that a minute amount of Taq polymerase, approximately 
1unit (but no more than 2 units) is need to carry out PCR, as an excess may 
cause the amplification of non-target sequences (Chawla, 2000). 
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 Comprehending the central components of PCR is vital for further 
understanding its complexity.  PCR is best conveyed when broken into its 
central components.  Three significant components of PCR include: 
1. Known nucleotide sequences, at both ends of the selected DNA region 
to be amplified, allow for DNA primers (both forward and reverse) to 
anneal to the targeted DNA molecule. 
2. The sole function of DNA primers is to demarcate the region of DNA 
that will be enzymatically amplified.  DNA primers are also known as 
oligonucleotides, which are short, synthesized sequences of DNA or 
RNA that are typically 25 nucleotides or fewer in length.   
3. Taq polymerase, or DNA polymerase 1 from Thermus acquaticus4, is 
necessary for the amplification of the selected DNA region.  Taq 
polymerase, a thermostable enzyme discovered by Kary Mullis, ably 
endures denaturation in environments up to 94 degrees Celsius.  The 
Klenow fragment, obtained from DNA polymerase 1 in E. coli, was 
initially used to execute PCR.  While functional and structural 
properties of Taq polymerase resembled those of DNA polymerase 1 
of E. coli (Joyce and Grindley, 1983), DNA polymerase 1 was ill-
suited for the denaturation cycle in PCR.   
Other important components included in PCR are the amplification buffer, 
which typically contains KCl, Tris-chloride, and MgCl2, and 
deoxyribonucleoside triphosphates (DNTPs) at a concentration of 200 µM 
(Chawla, 2000).   
                                                 
4
Thermus acquaticus is a bacterium native to hot springs.   
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Additional Functions of Taq Polymerase 
 Taq polymerase functions to replace nucleosides in DNA repair and 
also remove RNA primers during the processing of Okazaki fragments 
(Kernberg and Baker, 1992).  In nucleotide editing reactions, two prominent 
domains allow Taq polymerase to exhibit dual functions.  The N-terminal 
domain has 5’-nuclease activity which cleaves RNA primers or defective 
DNA strands, and the C-terminal domain has DNA polymerase activity which 
synthesizes new DNA strands (Ho, D. et al., 2004).  One limitation to the 
function of Taq polymerase is its lack of 3’ to 5’ exonuclease activity.  It is 
thereby unable to proofread and remove mismatched bases making it slightly 
less efficient than other naturally existing polymerases.  Fortunately, other 
thermostable enzymes with proofreading capabilities have been isolated 
(Chawla, 2000).  In summary, the nuclease and polymerase activity of Taq 
polymerase has been utilized by Invitrogen to allow the non-template transfer 
of a solitary (A) to each 3’ end of the PCR product. 
 
2.3 PCR Product 
 Complementary DNA (cDNA) is a single-stranded DNA transcript 
synthesized from an mRNA template, and its synthesis is catalyzed by reverse 
transcriptase.  Once the cDNA transcript is produced, the second strand of 
cDNA is made from DNA polymerase 1.  Formation of the double-stranded 
cDNA may then be fused into a vector and cloned (Brown, 1990).   
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 Genomic DNA of cells containing cloned cDNA of bovine rhodopsin 
was used as a PCR template in my experiment.   The PCR product, cDNA of 
bovine rhodopsin, was contributed by Jeremy Nathans, et al. (1989).  In 
addition, Nathans et al. sub-cloned the cDNA encoding bovine rhodopsin and 
the protein was expressed in human cells.  When treated in vitro with 11-cis 
retinal, these cells containing the cloned cDNA of bovine rhodopsin generated 
a red pigment with an absorbance identical to the original bovine rhodopsin 
(Nathans, J. et al., 1989).   
 I used PCR to amplify the cDNA of bovine rhodopsin and to add new 
restriction enzyme sites using the template provided by Nathans.  The PCR 
product was then treated with Taq polymerase provided by the Invitrogen 
pBAD TOPO® cloning system, in order to add (A) overhangs required to 
ligate the PCR product to the 3’ (T) overhangs within the pBAD TOPO 
vector.  
 As previously mentioned, DNA primers are needed to mark or isolate 
the region of DNA that will be enzymatically amplified.  The following DNA 
primers, as shown in Figure-2.1, were designed and purchased for the PCR 
product.  The forward primer begins with an in-frame stop codon (TAG) and 
is subsequently followed by the ribosome binding site (AGGA) which 
functions as a translation re-initiation sequence.  The ATG start codon of the 




Figure-2.1 Forward and Reverse DNA primers used in the PCR amplification of the cDNA 
encoding bovine rhodopsin.  DNA primers mark the region where the bovine rhodopsin gene 
will be amplified during PCR. 
 
This construction of the rhodopsin polypeptide sequence permits 
expression from the araBAD promoter without the enterokinase leader 
sequence. Devoid of the protective space provided by the 6 nucleotides 
(between the ribosome binding site (AGGA) and the start codon (ATG)), the 
bacterial cells would be incapable of restarting translation.  Additionally, 
restriction endonucleases, BamHI and NdeI, were introduced into the forward 
primer.  HindIII, also a restriction endonuclease, was introduced in the reverse 
primer as well.  To summarize, the purpose of the introduced restriction 
enzyme sites was to provide sites where N- or C-terminal modifications of the 
rhodopsin sequence could be inserted.   
 
2.4 TOPO® Cloning Reaction 
 With the presence of the cloning vehicle (pBAD TOPO® vector) and 
PCR product from the prospective gene to be cloned (cDNA encoding bovine 
rhodopsin), the cloning process was executed.   
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1. In sequential order: 1 microliter (µl) of the PCR product containing the 
cDNA of the bovine rhodopsin protein, 1 µl of salt solution 
(concentration of 1.2 M NaCl and 0.06 M MgCl2), 3 µl of sterile 
water, and 1 µl of the pBAD TOPO® vector (for a final volume of 6 
µl) were added to a sterile 1.5 milliliter (ml) test tube.  The reagents 
were mixed gently and allowed to rest undisturbed at room 
temperature (21-23 ˚C) for a total incubation time of 5 minutes.  The 
(A) overhangs within the PCR product easily allowed its ligation to the 
(T) overhangs in the pBAD TOPO® vector, constituting the complete 
insertion of the PCR product into the plasmid.   
2. The cloning reaction (from the previous step) was placed on crushed 
ice after 5 minutes.  Once chilled, 1 µl of the cloning reaction was 
added to a microcentrifuge tube containing 50 µl of thawed (on ice), 
competent cells E.coli cells strain XL-1 blue (Stratagene).  Competent 
cells are especially efficient at DNA re-uptake.  It is believed that 
MgCl2 (or another salt) causes the DNA to precipitate and adhere to 
the outside of the E.coli cell walls.  When the E.coli cells are chilled 
and immersed in cold salt-solution, they are more proficient in DNA 
uptake than untreated cells.  However, the DNA does not enter the 
treated cells, but instead, remains attached to the exterior of the cell 
walls.  Only when the chilled cells are shocked or quickly heated to 
42˚C does the DNA enter the competent cells (Brown, 1990).   
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3. The tube of competent E.coli cells were placed in a hot water bath 
(stabilized to 42˚C) and heat-shocked for 30 seconds.  Immediately, 
the vial of cells were transferred to ice and incubated between 10-15 
minutes. 
4. 250 µl of room temperature SOC medium (containing 2% tryptone, 
0.5% yeast extract, 10 mM NaCl, 2.5 mM KCl, 10 mM MgCl2, 10 mM 
MgSO4, and 20 mM glucose) was added to the competent cells. 
5. The vial of cells was incubated at 37˚C for 1 hour in a non-shaking 
incubator. 
6. 100 µl of the cells were added and evenly spread on a room 
temperature LB-ampicillin plates and incubated (in a non-shaking 
incubator) at 37˚C overnight.   
 
2.5 Selection and growth of colonies 
 A single colony resulted from the TOPO® Cloning reaction.  This was 
inoculated in a capped, sterile 10 ml test tube containing 2 ml of sterile LB 
media (per liter: 10g tryptone, 5g yeast extract, 10g NaCl, and distilled H2O, 
adjusted to a pH of 7.0 using NaOH) and 2 µl of filter-sterilized ampicillin (50 
mg/ml).  The tube was incubated for 16 hours at 37˚C in a non-shaking 
incubator.   
 The following day, 1 ml of the cells and 40 µl of ampicillin (50 
mg/ml) were added to a 125 ml flask of 40 ml of sterile LB media and grown 
in a shaker bath overnight at 37˚C.   
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2.6 DNA Purification of the cloned cells 
 Plasmid DNA from the cloned cells was purified using Wizard® Plus 
SV Minipreps DNA Purification System.   
Harvesting of Cells 
1. 1.5 ml (from the 40 ml of cells) was added to a sterile 1.5 ml 
microcentrifuge tube and centrifuged at 10,000 rpm for 5 minutes.   
2. The supernatant was decanted and excess liquid was removed by 
inverting the tube and gently blotting it on a kimwipe.       
Purification  
1. 250 µl of Cell Resuspension solution (50 mM Tris-HCl at pH 7.5, 10 
mM EDTA, and 100 µg/ml RNase A) was added to the pelleted cells.  
By gently pipetting the solution, the pellet was thoroughly 
resuspended. 
2. 250 µl of Cell Lysis solution (0.2 M NaOH, 1% SDS) was added to 
the tube of cells.  Cell lysis solution lyses open the cells allowing the 
DNA (and inside contents) to enter solution.  The tube was inverted 4 
times and incubated at room temperature until the lysate cleared.  (The 
solution takes on a slimy, viscous consistency).  
3. Although not a crucial step, 10 µl of Alkaline Protease solution was 
added to the tube and inverted 4 times.  The sole purpose of the 
protease solution is to deactivate endonucleases and other degrading 
enzymes released into the solution during cell lysis.  These proteins 
may degrade the quality of DNA by nicking portions. 
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4. 350 µl of Neutralization solution (4.09M guanidine hydrochloride, 
0.759M potassium acetate, and 2.12M glacial acetic acid at a pH of 
4.2) was added to the test tube.  Sufficient mixing of the contents was 
done by inverting the tube 4 times.  The acidity of the Neutralization 
solution restabilizes the pH to neutral, as too basic a pH damages DNA 
by denaturation. 
5. The test tube was centrifuged at 10,000 rpm for 10 minutes at room 
temperature5 to separate the soluble products (DNA) from the solid 
bacterial matter.    
Centrifuging the lysate 
1. Approximately 850 µl of the cleared lysate was extracted from the 
white precipitate (carefully avoiding the transfer of the precipitate) and 
transferred to a spin column (already inserted in the 2 ml collection 
tube).   
2. The spin column and its contents were centrifuged at 10,000 rpm for 1 
minute and the flow-through was discarded.  At this point, the DNA 
binds to the spin column, and all the soluble, excess materials (e.g., 
junk DNA and soluble proteins) are removed in the filtrate. 
3. 750 µl of Column Wash solution6 (previously diluted with 35 ml of 
95% ethanol) was added to the spin column and centrifuged at 10,000 
rpm for 1 minute.  The flow-through was subsequently discarded.  
Ethanol precipitates the DNA, which continues to adhere to the spin 
                                                 
5 The entire DNA purification process was carried out at room temperature.   
5 The Column wash solution contains 60% ethanol, 60 mM potassium acetate, 8.3 mM Tris-
HCl, 0.04 mM EDTA). 
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column.  Any trace amounts of residual proteins are removed in the 
flow-through.   
4. 250 µl of Column wash solution was added to the spin column and 
centrifuged for 2 minutes.  
5. The spin column was removed, blotted with a Kimwipe to remove 
excess column wash solution and transferred to a sterile 1.5 ml 
microcentrifuge tube.  
6. 60 µl of Nuclease free water was added to the spin column.  The tube 
was centrifuged for 1 minute at 10,000 rpm for 1 minute and stored in 
the freezer at -20˚C.  Water resolubilizes the DNA, permitting easy 
passage through the spin column.     
 
2.7 Analysis of the Plasmid DNA 
 The orientation of the bovine rhodopsin gene within the pBAD TOPO 
plasmid was analyzed by restriction endonuclease (restriction enzyme) 
treatment and agarose gel electrophoresis.  By performing enzymatic digests 
on the DNA sample, the generation of DNA fragments of varying sizes 
directly resulted from the location of the restriction enzyme sites in the DNA 
sample.  An agarose gel aided in the process of separating the DNA fragments 
and created a visual depiction of the gene’s orientation.      
Restriction endonuclease digests 
 The purified plasmid DNA was treated with restriction endonucleases, 
NcoI, BamHI, and HindIII.  Single digests and double digests were 
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performed.  For the single digests: 5 µl of the DNA sample, 1 µl of 10x 
Buffer, and 1 µl of the restriction endonuclease (totaling 7 µl) were added to a 
sterile 0.6 ml microcentrifuge tube.  For the double digests: 5 µl of the DNA 
sample, 2 µl of 10x buffer, and a total of 2 µl of restriction endonucleases 
(totaling 9 µl) were added to a 0.6 ml microcentrifuge tubes.  Three double 
digests were made in the following combinations: NcoI and HindIII, NcoI and 
BamHI, and BamHI and HindIII.  All samples were incubated in a non-
shaking incubator for 1 hour at 37˚C.    
Gel preparation  
 A 0.8% agarose gel was made using 0.4g of agarose7 10 ml of 5x TBE 
buffer (made from 2.7g Tris base, 1.38g boric acid, and 1 ml EDTA in 50 ml 
of distilled H2O), and 40 ml of distilled H2O.  The ingredients were added to a 
125 ml flask and heated until the agarose dissolved.  When the solution 
roughly cooled to 40˚C, 3 drops of ethidium bromide stock solution (0.5 g/ml) 
was added.  The solution was poured in a gel-casting mold and allowed to 
solidify.  After solidification, the gel was loaded in a horizontal gel box and 
200 ml of diluted 5x TBE solution (40 ml of buffer in 160 ml of distilled H2O) 
to which  3 drops of ethidium bromide were added.   
 Running samples on the Gel 
1. 2 µl of gel loading buffer (with tracking dye) were added to each of 
the 3 single digests and 3 double digests.   
                                                 
7 The agarose was made by Fisher BioReagents and has a high melting temperature suitable 
for separation of large DNA molecules. 
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2. 5 µl of a DNA ladder8 (Gene choice molecular weight standards), 9 µl 
of each of the single digests and 10 µl of each of the double digests 
were added to the wells of the gel. 
3. The gel ran between 30 and 45 minutes in duration at 150 volts. 
4. A UV-trans-illuminator/camera Gel Doc (Kodak) provided an image 
of the gel, making analysis possible. 
 
2.8 Transformation 
 After determining the orientation of the bovine rhodopsin gene within 
the pBAD TOPO plasmid, E.coli cells from strain UT5600 were transformed.  
As an advantageous method, transformation promotes the acquisition and 
integration of extrachromosomal DNA into a bacterial cell’s chromosome.  
While many bacterial strains are adept in DNA uptake from their 
environments, transformation is not entirely efficient primarily because of 
DNA degradation9.  Easy distinction between cells with successful 
transformation and those lacking the plasmid DNA involves the expression of 
specific genes by the plasmid DNA.  The presence of an ampicillin resistance 
gene within the plasmid markedly distinguishes the transformed cells from the 
non-transformed cells.  Antibiotic resistant genes are transferred to the host 
cell in cloning reactions.  Cells that lack the ampicillin-resistant gene are 
unable to grow on agar plates containing ampicillin (Brown, 1990).   
                                                 
8 The DNA ladder determines the size of DNA molecules ranging from 200 to 12,000 base 
pairs in length.  5 µl of the ladder contains 1% agarose in 1x TAE buffer stained with 
ethidium bromide.   
9 Uptaken DNA often experiences degradation by the host cell.   
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Procedure 
 Transformation of E.coli cells from strain UT5600 was completed 
using 1 µl, 2 µl, and 5 µl of the purified recombinant plasmid DNA (pBAD 
TOPO + bovine rhodopsin).   
1. Three, 1.5 ml microcentrifuge tubes containing 50 ml aliquots of the 
E.coli cells (stored -70˚C) were thawed in crushed ice.   
2. 1 µl, 2 µl, and 5 µl of the purified plasmid DNA were added to the 
tubes.  The contents of the tubes were mixed with gentle stirring of the 
pipette tip.   
3. The tubes were incubated on ice for 5 minutes. 
4. Cells were heat shocked at 42˚C in a water bath for 45 seconds.   
5. Immediately after heat shocking, the tubes were placed on ice. 
6. 200 µl of sterile LB media without ampicillin was added to each of the 
3 tubes. 
7. The tubes were incubated in a non-shaking incubator at 37 ˚C for 1 
hour. 
8. 100 µl of cells were taken from each of the 3 tubes and evenly spread 
onto LB plates containing ampicillin and incubated at 37 ˚C for 24 
hours.   
 
2.9 Protein Expression 
 Protein expression occurs in two stages, with the first being 
transcription and the second, translation.  A brief examination of transcription 
 26 
(with particular emphasis on initiation) sufficiently details the ability of the 
pBAD TOPO plasmid to express the bovine rhodopsin protein.  
Transcription10 is the process whereby an RNA transcript is synthesized from 
a DNA template.  Two important sub-phases within transcription are initiation 
and elongation.  
1. In the initiation phase (most crucial phase), RNA polymerase must 
detect and bind to the promoter11 in order to initiate transcription.  The 
promoter ultimately controls the expression of a gene.  For the bovine 
rhodopsin protein to be expressed, RNA polymerase must first bind to 
the pBAD promoter (which will subsequently be discussed).    
2. In the elongation phase, RNA polymerase reads the template DNA 
strand in the 5’ to 3’ direction while simultaneously adding the 
complementary RNA bases12.  RNA polymerase produces an RNA 
transcript complementary to the DNA strand encoding the bovine 
rhodopsin gene.  The RNA transcript is later translated into the bovine 
rhodopsin protein (Chawla, 2000).   
Promoter control of protein expression  
 The pBAD (araBAD) promoter permits the expression of the bovine 
rhodopsin protein.  Within the pBAD TOPO plasmid, the araC gene lies 
adjacent to the pBAD promoter (Wilcox et al., 1974) and positively and 
negatively regulates the pBAD promoter (Carra and Schleif, 1993; Lobell and 
                                                 
10 Transcription, one of two steps (the other being translation) in protein synthesis, is 
catalyzed by RNA polymerase.   
11 A promoter is a short DNA sequence located immediately upstream of the gene to be 
transcribed.   
12 The four RNA bases are uracil (U), guanine (G), cytosine (C), and adenine (A).   
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Schleif, 1990).  The presence of arabinose turns on transcription from the 
pBAD promoter.  Conversely, the opposite is true in the absence of L-
arabinose, as the pBAD promoter is suppressed by the araC gene resulting in 
minimal transcription levels (Lee, 1980; Lee et al., 1987). To summarize, the 
pBAD promoter, incorporated in the pBAD TOPO plasmid, functions to 
regulate heterologous gene expression of bovine rhodopsin in the E. coli cells 
(Guzman et al., 1995).   
Procedure 
1. A colony was selected from a transformation plate13 and inoculated 
into 2 ml of LB media and 2 µl of ampicillin (50 mg/ml) at 37 ˚C in a 
non-shaking incubator for 16 hours. 
2. The 2 ml overnight culture was added to a sterile 1 L flask containing 
350 ml of fresh, enriched LB media (per liter: 10g tryptone, 5g NaCl, 
5g yeast extract, 5g NaHPO4 (anhydrous) and 0.5% glycerol adjusted 
to pH 7.0) and 350 µl of ampicillin.  As the cells grow and consume 
glycerol in the LB media, they produce wastes that decrease the pH of 
the solution.  Fortunately, the phosphate buffer (HPO4
2-/ H2PO4
-) 
prevents a drastic lowering of pH that would otherwise occur.   
3. The flask was shaken at 200 rpm at 37˚C and the optical density of the 
culture was taken every 45 minutes to monitor cell growth. 
                                                 
13The plate was from the transformation reaction conducted with 5 µl of the purified plasmid 
DNA and E. coli cells strain UT5600.   
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After 4.5 hours, 3.5 ml of a 20% arabinose solution (made from 2g of L-
arabinose in 10 ml of distilled water) and approximately 2-5 µl of retinal 
stock solution (~50 µM) was added to the cells. 
4. The heat of the shaker bath was turned off14 and the cells were allowed 
to grow overnight at room temperature.   
5. The color of the cells was noted the following day. 
Cell lysis 
1. The 350 ml culture of cells was equally divided into 175 ml aliquots 
and added to two 400 ml centrifuge tubes. 
2. The cells were centrifuged at 4,000 rpm for 30 minutes at 4˚C.   
3. The supernatant was removed and 5 ml of cell lysis solution (in 20 
ml: 10 mM HEPES at pH 7.1, 1 mM PMSF protease inhibitor, 3% 
octyl glucoside, 0.08% lysozyme, and 0.01 mg/ml DNAse) was 
added to one of the centrifuge tubes (the other was stored at -20˚C). 
4. On ice, the cells were thoroughly resuspended with continuous gentle 
stirring and the lysate was transferred to a sterile, capped 50 ml 
centrifuge tube. 
5. The tube was incubated at 4˚C for approximately 70 hours.  
6. The lysate was centrifuged at 4,000 rpm for 20 minutes at 4˚C.  The 
supernatant was removed and used for spectral analysis.   
 
                                                 
14 Turning off the heat allows a gradual cooling of cells; otherwise overgrowth and minimal 
protein expression would occur.   
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Chapter 3 
Results and Conclusions 
 
3.1 Cloning Reaction 
With the appearance of a single colony, the probability of selecting a 
colony possessing the correct orientation15 of the bovine rhodopsin gene was 
only a 50% chance.  As luck would have it, it was not necessary to repeat the 
cloning steps to obtain additional colonies, 










Figure-3.1  Culture of cells from the only resulting 
colony of the cloning reaction.  
 
 
3.2 Restriction Enzyme Digests 
 A restriction enzyme digest was performed on the purified plasmid 
DNA containing the bovine rhodopsin gene in order to assess the orientation 
of the gene.  Restriction endonucleases recognize and cleave DNA at specific 
sequences.  NcoI recognizes the DNA sequence, 5’ C/CATGG 3’ and cleaves 
                                                 
15 It was possible for the bovine rhodopsin gene to be inserted into the pBAD TOPO plasmid 
in either the forward or reverse direction.  The correct orientation, and thus highly desired, is 
the forward direction.   
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between the two cytosines (C).  BamHI recognizes the 5’ G/GATCC 3’ 
sequence and cleaves between the two guanidines (G).  HindIII recognizes the 
sequence, 5’ A/AGCTT 3’ and cleaves between the two adenosines (A).  
Depending on the location of the location of the restriction enzyme sites in a 
DNA sequence, performing a digest on a DNA sample will generate 
fragments of varying sizes, indicating the direction or size of your DNA 
product.   
The purified plasmid recombinant DNA is approximately 5.2K base 
pairs.  As shown in Fig 3.2, capital letters represent the nucleotides sequence 
in the pBAD TOPO plasmid and lower case letters represent the bovine 
rhodopsin gene (id: NM_00104890).  Highlighted in green, red, and blue are 
the restriction enzyme sites of BamHI, NcoI, and HindIII respectively.   
NcoI has two sites in the recombinant plasmid DNA.  The first is 342 
base pairs from the first nucleotide and the second is 498 base pairs from the 
first nucleotide.  Counting from the bottom, the first NcoI site is 4,696 base 
pairs from the last nucleotide and the second site is 4,582 base pairs from the 
last.  BamHI also has two three in the recombinant plasmid DNA.  The first 
site is 237 base pairs from the first nucleotide, the second is 353 base pairs 
from the first nucleotide, and the third site begins at 390 base pairs from the 
first nucleotide.  Beginning at the bottom, the first site is approximately 4,957 
base pairs from the last nucleotide, the second site is 4,841, and the third is 
4,804 base pairs from the last nucleotide.  Hind 3 has only one site in the 
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recombinant plasmid DNA.  It is 1,451 nucleotides from the first nucleotide 
and 3,743 base pairs from the last nucleotide. 
 
 Figure-3.2  Sequence of the pBAD TOPO plasmid (obtained from the Invitrogen website) 
with the inserted bovine rhodopsin gene.  The DNA molecule is 5,202 base pairs in length and 
highlighted in blue, green, red, and blue are the restriction enzyme sites.   
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            Figure-3.3  Restriction enzyme digest performed on the purified plasmid DNA sample. 
 
Single and double digests were performed on the purified plasmid 
DNA containing the bovine rhodopsin gene was treated with restriction 
enzymes.  It is possible that the position of the cut sites have shifted and this 
may be to supercoiled DNA.     
The first lane from the left is the DNA ladder.  The second lane shows 
purified DNA from the pBAD TOPO with the added bovine rhodopsin gene.  
The uncut, supercoiled plasmid in lane 2 matches with the 4,000 base pair 
(bp) fragment, but is actually expected to have a total length of 5,000 bp.  The 
third lane shows the Nco1 cut sites with 2 two bands in very close proximity 
between the 6,000 and 5,000 bp fragments.  The fourth lane shows the BamHI 
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cut sites with the first band from the appearing between the 8,000 and 7,000 
bp fragments and the second appearing between the 6,000 and 5,000 bp 
fragments.  The fifth lane shows HindIII which only has one cut site, giving a 
clean band around the 5,000 base pair fragment.  In lane 6, the Nco1 sites 
(around 4,500 bp on the gel) and the HindIII (around 1,200 bp on gel) are in 
close proximity to their correct positions and should be far apart from one 
another.  In lane 7, appears to have one band, but the NcoI and BamHI sites 
are positioned close to one another in the actual DNA sequence.  In lane 8, the 
BamH1 and the HindIII cut sites are in the correct places at 5,000 bp and 
around 1,400 base pairs respectively.  If the bovine rhodopsin gene was 
inserted in the incorrect direction, a strong 1,400 bp fragment should have 
been visible in lanes 3, 4, and 7.  Moreover, the agarose gel displaying the 
digested DNA sample indicates the correct insertion of the bovine rhodopsin 
plasmid.   
 
3.3 DNA Sequence 
The purified plasmid DNA (concentration of 129 nanograms per 
microliter) and the pBAD forward sequencing primer (concentration of 0.1 
µg/µl in TE Buffer) was diluted to the required 1 pM/µl and sent to the SUNY 
DNA Sequencing Core Facility for sequencing.  In Figure-3.4, generated by 
BioEdit version 7.0, the adenines are labeled in green font, cytosines are 
labeled in blue font, guanidines are labeled in black font, and thymidines are 
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labeled in red font.  In addition, nucleotides labeled ‘N’, are of unknown 
identity and can be one of the four DNA bases.   
 
Figure-3.4  Fluorescent DNA sequence of the purified plasmid DNA was obtained from the 
SUNY DNA Sequencing Core Facility at SUNY Upstate Medical University and generated 
by the BioEdit (version 7) program.   
 
 Additionally, the DNA sequence obtained from the SUNY Sequencing 
Core Facility demonstrates the correct orientation of the bovine rhodopsin 
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gene within the pBAD TOPO plasmid.  Had the gene been inserted in the 
reverse direction, the generated DNA sequence (from sequencing) would have 
been the complement of the DNA sequence shown in Figure-3.5. 
 
Figure-3.5  DNA sequence of the bovine rhodopsin gene obtained from the purified plasmid 
DNA sequenced at the SUNY DNA Sequencing Core Facility. 
 
The obtained DNA sequence was compared to the nucleotide sequence 
records on the National Center for Biotechnology Information (NCBI) website 
using the Basic Local Alignment Search Tool (BLAST) program (Altschul et 
al., 1990) and Figure-3.6 shows the results.  The purified plasmid DNA 
sequence generated a 96% match with NM_001014890, Bos taurus rhodopsin, 
due to gaps or mismatched bases, shown in Figure-3.6.  All of the errors were 
after the 531st nucleotide and therefore probably not significant.  Most DNA 
sequencing facilities can accurately sequence DNA molecules up to 500 bp in 
length.  DNA fragments larger than 500 bp are usually sequenced with 
inconsistencies beyond the 500th base.  
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 Figure-3.6  Results of query generated by the BLAST program on the NCBI website. 
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3.4 Transformation 
 After determining the correction orientation of the bovine rhodopsin 
gene in the pBAD TOPO plasmid, the purified DNA (from the DNA 
purification step) was used to transform E.coli cells strain UT5600, and the 
resulting colonies were expected to contain the recombinant DNA molecule.  
The presence of an ampicillin resistant gene within the pBAD TOPO plasmid 
assured the transfer of ampicillin resistance to the E.coli cells by uptake of the 
recombinant DNA molecule.  Consequently, only the E.coli cells with the 
recombinant DNA molecule could survive on the LB/ampicillin plates.   
 
Figure-3.7  Colonies from the transformation reaction with the recombinant DNA molecule 
and E.coli cells strain UT5600.   
 
3.5 Protein Expression 
 As stated previously, when retinal is added to rhodopsin a red to 
purple color is emitted.  Regrettably, the cells were not the anticipated red 
color; instead, they were an orange-brown color as shown in Figure-3.8. The 
lysate exhibited an orange-brown in color instead of the expected red, which 
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we believed to be metarhodopsin III, a semi-stable intermediate formed by the 
linkage between all-trans retinal and the opsin apoprotein (Bauman, 1972; 
Blazynski and Ostroy, 1984; Chabre and Breton, 1979; Ebrey, 1968).   
 
 
Figure-3.8  E.coli cells lysed with the cell lysis solution.  The resulting supernatant was an 
orange-brown color.   
 
 
 The metarhodopsin III intermediate absorbs light in the 470 nm region, 
and to test for the presence of metarhodopsin III in the lysate, a spectrum was 
taken between 190 and 700 nm to confirm its presence.  The spectral results 
are shown in Figure-3.9.  Although no defined spectral peak at 470 nm was 
observed, there is broad absorbance throughout the region above 400 nm.  We 
believe this could be due to the presence of a mixture of different photostates 
and/or of partially folded states of rhodopsin in our sample.       
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 Figure-3.9  Spectra taken on the lysate 
 
3.6 Conclusions 
 The bovine rhodopsin gene has been successfully cloned into E. coli 
cells strain UT5600.  Evidence garnered from the restriction enzyme digest, 
sequence of the purified DNA sample, BLAST results, and the successful 
transformation of the E. coli cells supports this conclusion.  However, the 
ability of the cells to express the bovine rhodopsin protein in a native or near-
native form is inconclusive and needs further investigation.  
 Future work on this experiment surrounds refinement of the protein 
purification process and possible attainment of crystals from the purified 
bovine rhodopsin protein.  We want to modify the rhodopsin gene to include 
parts of the proteorhodopsin gene that permit citrate induced precipitation.  
Ultimately, we want to crystallize the structure of bovine rhodopsin expressed 
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in the bacteria in order to compare it to known crystal structures of the bovine 














































Altschul SF, Gish W, Miller W, Myers EW, Lipman DJ (1990): Basic local alignment search 
tool.  J Mol. Biol. 215:403-410. 
 
Baumann, C (1972): Kinetics of slow thermal reactions during the bleaching of rhodopsin in 
the perfused frog retina. J Physiol. 222:643-663. 
 
Blazynski C and Ostroy S (1984): Pathways in the hydrolysis of vertebrate rhodopsin. Vision 
Res 24:459-470.  
 
Brown, T. A. (1990): Gene Cloning: An Introduction. 2nd Ed., St. Edmundsbury Press Ltd, 
Great Britain. 
 
Carra J, Schleif R (1993): Variation of half-site organization and DNA looping by AraC 
protein. EMBO J. 12:35-44. 
 
Chabre M and Breton J (1979): The orientation of the chromophore of vertebrate rhodopsin in 
the “meta” intermediate states and the reversibility of the meta II–meta III transition. 
Vision Res. 19:1005-1108. 
 
Chawla, H. S. (2000): Introduction to Plant Biotechnology. Enfield, NH: Science Publishers 
Inc. 
 
Ebrey T (1968): The thermal decay of the intermediates of rhodopsin in situ. Vision Res. 
8:965-982. 
 
Ebrey T, Koutalos Y (2001): Vertebrate photoreceptors. Prog Retin Eye Res. 20:49-94. 
 
Filipek S, Stenkamp R, Teller D, Palczewski K (2003b): G protein-coupled receptor 
rhodopsin: A prospectus. Annu Rev Physiol. 65:851-879.  
 
Fredriksson R, Schioth HB (2005): The Repertoire of G-Protein–Coupled Receptors in Fully 
Sequenced Genomes. Mol. Pharmacol. 67:1414 – 25. 
 
Guzman L, Barondess J, Beckwith J (1992): FtsL, and Essential Cytoplasmic Membrane 
Protein Involved in Cell Division in E. coli. J. Bacteriol. 174:7716-7728.   
 
Hargrave P (2001): Rhodopsin structure, function, and topography the Friedenwald lecture. 
Invest Opthalmol Vis Sci. 42:3-9. 
 
Heck M, Schäde S, Maretzski D, Hofmann K (2003): Secondary binding sites of retinoids in 
opsin: characterization and role in regeneration. Vision Res. 43:3003-3010.  
 
Heideman W, Bourne H (1990): Structure and Function of G-Protein α-chains. p. 17-40. In R 
Iyengar, L Birnbaumer (eds.), G Proteins. Academic Press Inc., San Diego, CA.  
 
Ho D, Byrnes W, Ma W, Shi Y, Callaway D, Bu Z (2004): Structure-specific DNA-induced 
Conformational Changes in Taq Polymerase Revealed by Small Angle Neutron Scattering. 
J. Biol. Chem. 279:39146-39154.   
 
Joyce C, Grindley N (1983): Construction of a plasmid that overproduces the large proteolytic 
fragment (Klenow fragment) of DNA polymerase I of Escherichia coli. Proc. Natl. Acad. 
Sci. USA. 80:1830-1834. 
 
 42 
Kernberg A, Baker T (1992): DNA Replication, 2nd Ed., WH Freeman and Co., San 
Francisco. 
 
Lee N (1980): Molecular aspects of ara regulation, p. 389-410. In J Miller and W Reznikoff 
(eds.), The operon. Cold Spring Harbor Laboratory, Cold Spring Harbor, NY.   
 
Lee N, Francklyn C, Hamilton E (1987): Arabinose-induced binding of AraC protein to araI2 
activates the araBAD operon promoter.  Proc. Natl. Acad. Sci USA. 84:8814-8818.  
 
Lefkowitz RJ (2004): Historical review: A brief history and personal retrospective of seven-
transmembrane receptors. Trends Pharmacol. Sci. 25:413–22.  
 
Li J, Edwards P, Burghammer M, Villa C, Schertler G (2004): Structure of bovine rhodopsin 
in a trigonal crystal form. J Mol Biol. 343:1409–1438. 
 
Lobell R, Schleif R (1990): DNA looping and unlooping by AraC protein. Science. 250:528-
532.   
 
Menon S, Han M, Sakmar T (2001): Rhodopsin: Structural Basis of Molecular Physiology. 
Physiol. Rev. 81:1659-1688. 
 
Mirzadegan T, Benko G, Filipek S, Palczewski K (2003): Sequence Analyses of G-Protein-
Coupled Receptors: Similarities to Rhodopsin. Biochemistry. 42:2759–67. 
 
Muller G (2000): Towards 3D structures of G protein-coupled receptors: A multidisciplinary 
approach. Curr Med Chem. 7:861–888. 
 
Nathans J, Weitz C, Agarwal N, Nir I, Papermaster D (1989): Production of bovine rhodopsin 
by mammalian cell lines expressing cloned cDNA: Spectrophotometry and subcellular 
localization. Vision Res. 29:907-914.  
 
Okada T, Ernst O, Palczewski K, Hofmann K (2001): Activation of rhodopsin: new insights 
from structural and biochemical studies. Trends Biochem. Sci. 26:318-324. 
 
Okada T, Palczewski K (2001): Crystal structure of rhodopsin: Implications for vision and 
beyond. Curr Opin Struct Biol. 11:420-426. 
 
Okada T, Takeda K, Kouyama T (1998): Highly selective separation of rhodopsin from 
bovine rod outer segment membranes using combination of divalent cation and alkyl 
(thio) glucoside. Photochem Photobiol. 67:495-499. 
 
Palczewski K, Kumasaka T, Hori T, Behnke C, Motoshima H, Fox B, Le Trong I, Teller D, 
Okada T, Stenkamp R, Yamamoto M, Miyano M (2000): Crystal structure of rhodopsin: 
A G protein-coupled receptor. Science.  289:739–745. 
 
Pierce KL, Premont RT, Lefkowitz RJ (2002): Seven-transmembrane receptors. Nat. Rev. 
Mol. Cell Biol. 3:639–50.  
 
Rasmussen S, Choi HJ, Rosenbaum D, Kobilka T, Thian F, Edwards P, Burghammer M, 
Ratnala V, Sanishvili R, Fischetti R, Schertler G, Weis W, Kobilka B (2007): Crystal 
structure of the human ß2 adrenergic G-protein-coupled receptor. Nature. 450:383-387. 
 
Salom D, Li N, Zhu L, Sokal I, Palczewski K (2005): Purification of the G Protein-Coupled 
Receptor Rhodopsin for Structural Studies. p. 1-17.  In S George, O’Dowd (eds.), G 
Protein-Coupled Receptor-Protein Interactions. John Wiley & Sons Inc., Hoboken, NJ. 
 
 43 
Salom D, Lodowski D, Stenkamp R, Trong I, Golczak M, Jastrzebska B, Harris T, Ballesteros 
A, Palczewski K, (2006). Crystal structure of a photoactivated deprotonated intermediate 
of rhodopsin. PNAS. 103:16123-16128. 
 
Sautel M, Milligan G (2000): Molecular manipulation of G-protein-coupled receptors: A new 
avenue into drug discovery. Curr Med Chem. 7:889–896. 
 
Shichida Y, Yamashita T (2003): Diversity of visual pigments from the viewpoint of G 
protein activation–comparison with other G protein-coupled receptors. Photochem. 
Photobiol. Sci. 2:1237-1246. 
 
Shuman S (1991a): Site-Specific DNA Cleavage by Vaccinia Virus DNA Topoisomerase I. J. 
Biol. Chem. 266:1796-1803. 
 
Shuman S (1991b): Site-Specific Interaction of Vaccinia Virus Topoisomerase I with Duplex 
DNA. J. Biol. Chem. 266:11372-11379. 
 
Shuman S (1994): Novel Approach to Molecular Cloning and Polynucleotide Synthesis Using 
Vaccinia DNA Topoisomerase. J Biol Chem. 269:32678-32684. 
 
Shuman S, Moss B (1987): Identification of a Vaccinia Virus Gene Encoding a Type I DNA 
Topoisomerase. Proc. Natl. Acad. Sci. USA. 84:7478-7482. 
 
Shuman S, Prescott J (1990): Specific DNA Cleavage and Binding of Vaccinia Virus DNA 
Topoisomerase I. J. Biol. Chem. 265:17826-17836. 
 
Tachibanaki S, Imai H, Terakita A, Shichida Y (1998): Identification of a new intermediate 
state that binds but not activates transducin in the bleaching process of bovine rhodopsin. 
FEBS Lttrs. 425:126-130. 
 
Takeda S, Kadowaki S, Haga T, Takaesu H, Mitaku S (2002): Identification of G protein-
coupled receptor genes from the human genome sequence. FEBS Lett. 520:97–101.  
 
Trabanino R, Hall S, Vaidehi N, Floriano W, Kam V, Goddard W (2004): First Principles 
Predictions of the Structure and Function of G-Protein-coupled Receptors: Validation for 
Bovine Rhodopsin. Biophys J.  86:1904-1921.   
 
Wilson S, Bergsma D (2000): Orphan G-protein-coupled receptors: novel drug targets for the 
pharmaceutical industry. Drug Des. Discov. 17:105–114. 
 
Wilcox G, Boulter J, Lee N (1974): Direction of Transcription of the Regulatory Gene araC 
in Escherichia coli B/r. Proc. Natl. Acad. Sci. USA. 71:3635-3639.   
 
Wilson S, Bergsma D, Chambers J, Muir A, Fantom K, Ellis C, Murdock P, Herrity N, Stadel 
J (1998): Orphan G-protein-coupled receptors: the next generation of drug targets? Br. J. 
Pharmacol. 125:1387–1392. 
 
Wolken, J (1995): Light Detectors, Photoreceptors, and Imaging Systems in Nature. New 











 G-protein coupled receptors (GPCRs) make up a total of ~950 genes in 
the human genome (Fredriksson and Schioth, 2005; Mirzadegan et al., 2003; 
Takeda et al., 2002).  GPCRs are important because they play a vital role  in 
cell signaling in that they relay extracellular messages to a cell’s interior; they 
detect and mediate hormones (Heideman and Bourne, 1990); and they are 
involved in electron transfer and ion transport, (Trabanino et al., 2004) critical 
functions for nerve impulses and other biochemical processes.   
 Additionally, properly functioning GPCRs are imperative for normal 
body function.  Minor mutations in GPCR structures result in diseases such as 
diabetes and hypertension, dwarfism, obesity, and retinitis pigmentosa 
(Wilson, et al., 1998).  Other manifested conditions resulting from deficient 
GPCRs include: allergies, anxiety, asthma, congestive heart failure, migraines, 
Parkinson’s, and ulcers (Wilson and Bergsma, 2000).  As you can imagine, a 
malfunctioned GPCR is potentially deadly.   
 However, much of what is currently known about GPCR structure was 
based on X-ray crystallographic measurements of rhodopsin.  This was the 
only GPCR with a known structure until the recent determination of the 
crystal structure of the human ß2 adrenergic G-protein coupled receptor 
(Rasmussen et al., 2007).  Of the presently available therapeutic drugs, 
approximately 40% of them target GPCRs (Muller, 2000; Sautel et al., 2000).  
The goal of finding new pharmaceuticals would be aided if the identity and 
structures of more GPCRS were known.   
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 Rhodopsin, the source of investigation in our experiment, has been 
extensively studied because it is readily available and accessible for 
manipulation, plays an important role in vision, and its active and inactive 
states are easily quantified (Ebrey and Koutalos, 2001; Hargrave, 2001; Okada 
et al., 2001; Okada and Palczewski, 2001; Filipek et al., 2003(b)).    Further, 
earliest crystallized structures of rhodopsin have provided information its 
helical arrangements and interactions, chromophore binding site, and 
extracellular ligand binding interactions in other types of GPCRs (Palczewski 
et al., 2000).  
 In the current experiment, the gene for bovine rhodopsin protein, a 
mammalian gene, was cloned into Escherichia coli (E.coli) cells strain 
UT5600.  The main goal was to assess the capability of a GPCR to be 
expressed in large quantities as a functional protein in bacterial cells.  
Successful expression of bovine rhodopsin in E.coli could pave the way for 
cheaper and less complex of GPCR proteins suitable for crystallization trials.   
 The pBAD TOPO TA Expression kit purchased from Invitrogen was 
used to conduct the cloning process.  PCR (Polymerase chain reaction) was 
used to amplify the prospective gene to be cloned, cDNA of bovine rhodopsin.  
The gene, in the form of bovine rhodopsin cDNA, was contributed by Jeremy 
Nathans, et al. (1989).    
 Cloning is the process whereby a gene is manipulated and inserted into 
an organism in which it is not naturally found (Brown, 1990).  In the TOPO® 
Cloning reaction, the bovine rhodopsin gene was inserted into the pBAD 
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TOPO plasmid to form a recombinant DNA molecule.  The recombinant DNA 
molecule, when uptaken by the E. coli cells strain XL-1 blue, made copies of 
itself along with the bovine rhodopsin gene.  As a single E. coli cell divided, 
copies of the recombinant DNA molecule were passed on to its progeny.  The 
E. coli cell continued to divide until it formed a colony, or cluster of cells.   
 A single colony resulted from the TOPO® Cloning reaction and was 
subsequently grown in a 40 ml flask containing LB media (food for the 
bacteria).  One and a half milliliters were taken from the culture and DNA was 
extracted from the cells and purified using a Wizard® Plus SV Minipreps 
DNA Purification System.   
 The purified plasmid DNA containing the cloned PCR product was 
treated with restriction enzymes and then analyzed on a 0.8% agarose gel to 
determine the correct orientation of the bovine rhodopsin gene.  Restriction 
enzymes cut DNA at specific sequences.  So treating the DNA sample with 
restriction enzymes produced DNA fragments of varying sizes based on the 
location of the restriction enzyme sites in the DNA sample.  The agarose gel 
aided in the process of separating the DNA fragments and created a visual 
depiction of the gene’s orientation.  Based on the results of the gel, we 
determined the bovine rhodopsin gene to be inserted in the correct direction in 
the pBAD TOPO plasmid.  Furthermore, the DNA was sequenced and 
compared to the nucleotide sequence records on the National Center for 
Biotechnology Information (NCBI) website using the Basic Local Alignment 
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Search Tool (BLAST) program (Altschul et al., 1990) and was determined to 
have the correct orientation.   
 The purified plasmid DNA was used to transform E. coli cells strain 
UT5600, and the resulting colonies were grown in growth media containing 
ampicillin.  To induce expression of rhodopsin, the sugar L-arabinose was 
added to the cells along with retinal (which causes the opsin protein to turn a 
red color).   
 The entire culture was centrifuged and the supernatant was removed.  
Cell lysis solution was added to the cells to extract the protein.  The lysate 
exhibited an orange-brown color, which we believed to be the result of all-
trans retinal (present as one of many isomers in the retinal stock solution that 
was added to the cells) combining with the opsin apoprotein (part of the 
rhodopsin protein) to form an intermediate called metarhodopsin III (Heck et 
al., 2003).   
 In summary, the bovine rhodopsin gene was successfully cloned into 
the bacterial cells, although the expressed protein was not completely refolded 
to the native rhodopsin form.  The sequenced DNA obtained from the SUNY 
DNA Sequencing Core Facility, BLAST query results, and restriction enzyme 
digests proves that the bovine rhodopsin gene was not only inserted into the 
E.coli cells but inserted with the correct orientation.  Also, the ability of the 
cells to express the bovine rhodopsin protein is inconclusive and needs further 
investigation.  Future work on this experiment surrounds refinement of the 
protein purification process and possible attainment of crystals from the 
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purified bovine rhodopsin protein.  We want to crystallize the structure of 
bovine rhodopsin expressed in the bacteria in order to compare it to known 
crystal structures of the bovine rhodopsin protein derived from cow eyes.        
 
 
